Results 51 to 60 of about 7,313 (199)

Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System

open access: yesFrontiers in Pharmacology, 2022
Esketamine was approved for the treatment of treatment-resistant depression in 2019. After the approval of esketamine, numerous concerns have been raised regarding its long-term safety and tolerability.
Haoning Guo   +6 more
doaj   +1 more source

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients with Treatment-Resistant Depression: A Randomized Clinical Trial [PDF]

open access: yes, 2019
Importance: Controlled studies have shown short-term efficacy of esketamine for treatment-resistant depression (TRD), but long-term effects remain to be established.
Bitter, I.   +22 more
core   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Sub-anesthetic dose of esketamine decreases postoperative opioid self-administration after spine surgery: a retrospective cohort analysis

open access: yesScientific Reports
The use of intraoperative sub-anesthetic esketamine for postoperative analgesia is controversial. In this study, the impact of sub-anesthetic esketamine on postoperative opioid self-administration was determined.
Hongyu Zheng   +5 more
doaj   +1 more source

Utilizing Esketamine Short-Term with New Oral Antidepressants in Patients with Treatment Resistant Depression and Suicidal Ideation to Minimize Post-Discharge Suicide Attempts: A Systematic Review [PDF]

open access: yes, 2023
Purpose: To assess whether esketamine can be utilized short-term while waiting for a new oral antidepressant to reach therapeutic level in patients admitted for treatment resistant depression and suicidal ideation.
Montgomery, Ebony SY
core   +1 more source

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang   +18 more
wiley   +1 more source

Effect of perioperative esketamine use on emergency delirium in children undergoing tonsillectomy and adenoidectomy: a systematic review and meta-analysis of randomized controlled trials

open access: yesFrontiers in Medicine
BackgroundEmergence delirium(ED) is a common postoperative complication in children undergoing tonsillectomy and adenoidectomy under general anesthesia. There is no high-quality evidence on the relationship between esketamine and ED.
Junfeng Liu   +6 more
doaj   +1 more source

A deep learning‐enabled toolkit for the 3D segmentation of ventricular cardiomyocytes

open access: yesThe Journal of Physiology, EarlyView.
Abstract figure legend 3D cardiomyocyte segmentation enables comprehensive analyses of myocardial microstructure in health and disease; however, it is technically demanding. We present an open‐source toolkit for this task, which reduces challenges associated with sample preparation, image restoration, segmentation and proofreading.
Joachim Greiner   +6 more
wiley   +1 more source

Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial

open access: yesBMC Psychiatry, 2019
Background There is an urgent need to develop additional treatment strategies for patients with treatment-resistant depression (TRD). The rapid but short-lived antidepressant effects of intravenous (IV) ketamine as a racemic mixture have been shown ...
Sanne Y. Smith-Apeldoorn   +6 more
doaj   +1 more source

Ketamine for the treatment of major depression: a systematic review and meta-analysis

open access: yes, 2023
Background: Intranasal esketamine has received regulatory approvals for the treatment of depression. Recently a large trial of repeated dose racemic ketamine also demonstrated efficacy in severe depression.
Bahji, A   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy